These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 9845094

  • 1. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):775-9. PubMed ID: 9845094
    [Abstract] [Full Text] [Related]

  • 2. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV, Ji M, Bloomer WD.
    Cancer Chemother Pharmacol; 2001 Aug 01; 48(2):160-8. PubMed ID: 11561782
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
    Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG.
    J Exp Ther Oncol; 2002 Aug 01; 2(5):298-305. PubMed ID: 12416033
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Aug 01; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):501-8. PubMed ID: 12451478
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN.
    J Natl Cancer Inst; 1992 Feb 05; 84(3):187-93. PubMed ID: 1542129
    [Abstract] [Full Text] [Related]

  • 12. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 1997 Feb 05; 9(5):249-57. PubMed ID: 9306432
    [Abstract] [Full Text] [Related]

  • 13. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    In Vivo; 1996 Feb 05; 10(1):49-57. PubMed ID: 8726811
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Basic Clin Pharmacol Toxicol; 2011 Jun 05; 108(6):396-9. PubMed ID: 21205223
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV, Ji X, Bloomer WD.
    Anticancer Res; 2005 Jun 05; 25(3B):2161-70. PubMed ID: 16158959
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E.
    Cancer Res; 1991 Feb 15; 51(4):1086-91. PubMed ID: 1825474
    [Abstract] [Full Text] [Related]

  • 18. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
    Teicher BA, Herman TS, Hopkins RE, Menon K.
    J Cancer Res Clin Oncol; 1992 Feb 15; 118(2):123-8. PubMed ID: 1735732
    [Abstract] [Full Text] [Related]

  • 19. Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.
    Papadopoulou MV, Bloomer WD, Torti VR, Page JG.
    Basic Clin Pharmacol Toxicol; 2010 Jun 15; 106(6):497-504. PubMed ID: 20074267
    [Abstract] [Full Text] [Related]

  • 20. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
    Papadopoulou MV, Bloomer WD.
    Clin Cancer Res; 2003 Nov 15; 9(15):5714-20. PubMed ID: 14654556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.